Maartje W. Rohaan, MD

MD, PhD student
Netherlands Cancer Institute, Division of Molecular Oncology and Immunology, Amsterdam, The Netherlands, Netherlands

Presentation(s):

• 61: Surgical considerations for tumor-infiltrating lymphocyte (TIL) therapy in melanoma: results from a randomized phase 3 trial.

  Thursday, March 21, 2024
  2:07pm – 2:17pm ET